- Home
- IMCR vs AVPT Comparison
IMCR vs AVPT Comparison
Compare IMCR & AVPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMCR | AVPT |
|---|---|---|
| Founded | 2008 | 2001 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 3.8B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | IMCR | AVPT |
|---|---|---|
| Price | $34.82 | $14.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $67.00 | $18.38 |
| AVG Volume (30 Days) | 269.1K | ★ 2.0M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | $379,590,000.00 | ★ $393,993,000.00 |
| Revenue This Year | $32.28 | $28.18 |
| Revenue Next Year | $10.66 | $17.77 |
| P/E Ratio | ★ N/A | $1,785.44 |
| Revenue Growth | ★ 28.11 | 24.71 |
| 52 Week Low | $23.15 | $11.49 |
| 52 Week High | $40.72 | $20.25 |
Technical Indicators
Market Signals| Indicator | IMCR | AVPT |
|---|---|---|
| Relative Strength Index (RSI) | 40.33 | 56.94 |
| Support Level | $35.41 | $13.37 |
| Resistance Level | $36.64 | $14.24 |
| Average True Range (ATR) | 1.51 | 0.33 |
| MACD | -0.25 | 0.05 |
| Stochastic Oscillator | 3.99 | 71.02 |
Price Performance
Historical ComparisonAbout IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About AVPT AvePoint Inc.
AvePoint Inc provides customizable solutions to optimize SaaS operations, enable secure collaboration, and accelerate digital transformation across technologies and industries. Its Confidence Platform delivers a comprehensive set of cloud-based solutions enabling IT operations, development operations, and cybersecurity professionals to monitor and secure the digital workplace using SaaS tools.